Table 1 Comparison of curative effects between patients with different clinical features [n (%)]
Variable | n | CR | PR | SD | PD | ORR | χ2 | P |
|---|---|---|---|---|---|---|---|---|
ECOG | ||||||||
1 | 11 | 0 | 3(27.3) | 6(54.4) | 2(18.2) | 3(27.3) | ||
2 | 14 | 0 | 2(14.3) | 8(57.1) | 4(28.6) | 2(14.3) | 7.731 | 0.021 |
≥ 3 | 6 | 0 | 0 | 1(16.7) | 5(83.3) | 0 | ||
Sex | ||||||||
Male | 17 | 0 | 2(11.8) | 10(58.8) | 5(29.4) | 2(11.8) | 0.606 | 0.436 |
Female | 14 | 0 | 3(21.4) | 5(35.7) | 6(42.9) | 3(21.4) | ||
Chemotherapy | ||||||||
Yes | 2 | 0 | 1(50.0) | 1(50.0) | 0 | 1(50.0) | 1.176 | 0.278 |
No | 29 | 0 | 14(48.3) | 14(48.3) | 11(37.9) | 14(48.3) | ||
Treatment lines | ||||||||
first-line | 8 | 0 | 3(37.5) | 3(37.5) | 4(50.0) | 3(37.5) | ||
second-line | 7 | 0 | 5(71.4) | 5(71.4) | 1(14.3) | 5(71.4) | 2.139 | 0.343 |
third-line | 16 | 0 | 7(43.8) | 7(43.8) | 6(37.5) | 7(43.8) | ||
metastatic sites | ||||||||
< 3 | 17 | 0 | 11(64.7) | 11(64.7) | 3(17.6) | 11(64.7) | 5.231 | 0.022 |
≥ 3 | 14 | 0 | 4(28.6) | 4(28.6) | 8(57.1) | 4(28.6) | ||